Acceleron’s Luspatercept to be showcased at ASH, says Piper Jaffray

Piper Jaffray analyst Danielle Brill kept her Overweight rating and $75 price target on Acceleron after holding meetings with its CEO Habib Dable. The analyst notes that investors’ primary focus continues to be on Luspatercept ahead of the “detailed Phase 3 MEDALIST data to be presented during the plenary session at ASH this weekend”. Brill adds that she is not expecting any major surprises but notes that any updates will likely be positive. The analyst further maintains her view that “luspatercept has blockbuster potential across a diverse range of anemias”, remaining bullish on the stock.

https://thefly.com/landingPageNews.php?id=2828823